Cognition Therapeutics, Inc. — Company profile
Healthcare · Biotechnology · United States
Last price 0.6982 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 66.39M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Company profile
Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is zervimesine, an orally delivered small molecule to protect neuronal synapses by preventing the binding of oligomers of pathogenic proteins, which is in Phase 2 clinical studies for the treatment of Alzheimer’s disease and Mild Cognitive Impairment, as well as geographic atrophy secondary to dry age-related macular degeneration and dementia with Lewy bodies. Cognition Therapeutics, Inc. was incorporated in 2007 and is based in Purchase, New York.
Details
| Name | Cognition Therapeutics, Inc. |
| Sector | Healthcare |
| Industry | Biotechnology |
| Employees | 14 |
| Founded | 2007 |
| Ipo Date | 2021-10-08 |
| Ceo | Lisa Ricciardi |
| Country | United States |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| Ipo Price | 12.00 |
| Isin | US19243B1026 |
| Cusip | 19243B102 |
| Cik | 1455365 |
| Sic | 2836 |
| Stock Type | Common Stock |
Key executives
| Name | Title |
|---|---|
| Lisa Ricciardi | Chief Executive Officer, President and Director |
| John Brendan Doyle | Chief Financial Officer |
| Dr. Anthony O. Caggiano M.D., Ph.D. | Chief Medical Officer |
| Dr. Steven A. Weissman Ph.D. | Vice President and Head of CMC |
| Anita Cornet | Head of Quality |
| Bobby Horn | Corporate Controller |
Contact
| Address | 2500 Westchester Ave., Purchase, New York 10577, United States |
| Phone | 412 481 2210 |
| Website | https://www.cogrx.com |